In addition, we show that cytotoxicity and migration properties of breast cancer cell lines treated with DHTS are influenced by HuR dosage, supporting the post-transcriptional effect of this compound as a new, therapeutically relevant molecular mechanism. The gene discussed is ELAVL1; the disease is breast carcinoma.